JNJ-49095397 (RV568) is a selective p38 MAPK-α and p38 MAPK--γ kinase inhibitor with anti-inflammatory activity and potential antiviral activity for chronic obstructive pulmonary disease (COPD), cystic fibrosis, and respiratory syncytial virus infection.

JNJ-49095397 (1 μg-1 g/mL; 4 h) demonstrates potent anti-inflammatory effects in monocytes and macrophages. When used in combination with corticosteroids, it exhibits synergistic anti-inflammatory effects in poly I:C-stimulated BEAS-2B cells and cigarette smoke models[1].

In non-fasted Balb/c mice, in the LPS-induced neutrophil accumulation model, JNJ-49095397 (1, 4, and 20 μg/mouse; intratracheal administration, 2, 8, or 12 h prior to LPS inhalation) prevented the accumulation of neutrophils in the BAL fluid. Significant inhibition of neutrophil accumulation was observed when administered up to 8 h prior to LPS inhalation[1].